Longer term benefit of dual antiplatelet therapy in stroke/TIA

 

The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial demonstrated that the addition of clopidogrel to low-dose ASA in Chinese patients with acute minor stroke or transient ischemic attack provided better protection against subsequent stroke compared to ASA alone (Wang et al. N Engl J Med 2013;369:11-19).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page